Concise Review: A High-Content Screening Approach to Stem Cell Research and Drug Discovery

Stem Cells ◽  
2012 ◽  
Vol 30 (9) ◽  
pp. 1800-1807 ◽  
Author(s):  
Xiaofeng Xia ◽  
Stephen T. Wong
Keyword(s):  
Stem Cell ◽  
Drug Discovery ◽  
Stem Cell Research ◽  
High Content Screening ◽  
Concise Review ◽  
Screening Approach

INSIDE INDUSTRY

2018 ◽  
Vol 22 (07) ◽  
pp. 46-51
Keyword(s):  
Stem Cell ◽  
Drug Discovery ◽  
3D Printing ◽  
Great Basin ◽  
Stem Cell Research ◽  
Personal Health ◽  
Standard Part ◽  
Tokyo Medical ◽  
Medical University ◽  
Oncology Center

Pharma companies are partnering AI firms to advance drug discovery. SGD110 million lab to create healthier foods and sustainable biochemicals. Philips and Singapore Institute of Advanced Medicine Holdings open regional oncology center. 3D printing will become standard part of healthcare portfolio. Vela Diagnostics buys Great Basin Scientific. APAC Biotech and Diakonos bring new immunotherapy technology to India. Kintaro Cells Power partners Tokyo Medical University to advance stem cell research. Clearbridge partners with Genome.One to offer personal health genomics programme.

scholarly journals Concise Review: Induced Pluripotent Stem Cell Research in the Era of Precision Medicine

Stem Cells ◽  
2017 ◽  
Vol 35 (3) ◽  
pp. 545-550 ◽  
Author(s):  
Takashi Hamazaki ◽  
Nihal El Rouby ◽  
Natalie C. Fredette ◽  
Katherine E. Santostefano ◽  
Naohiro Terada
Keyword(s):  
Stem Cell ◽  
Precision Medicine ◽  
Stem Cell Research ◽  
Pluripotent Stem Cell ◽  
Induced Pluripotent Stem Cell ◽  
Concise Review ◽  
Induced Pluripotent

scholarly journals Isolation of rat embryonic stem-like cells: A tool for stem cell research and drug discovery

2011 ◽  
Vol 240 (11) ◽  
pp. 2482-2494 ◽  
Author(s):  
M. Fernández ◽  
S. Pirondi ◽  
B. L. Chen ◽  
G. Del Vecchio ◽  
M. Alessandri ◽  
...  
Keyword(s):  
Stem Cell ◽  
Drug Discovery ◽  
Stem Cell Research ◽  
Embryonic Stem

scholarly journals High-throughput cellular microarray platforms: applications in drug discovery, toxicology and stem cell research

2009 ◽  
Vol 27 (6) ◽  
pp. 342-349 ◽  
Author(s):  
Tiago G. Fernandes ◽  
Maria Margarida Diogo ◽  
Douglas S. Clark ◽  
Jonathan S. Dordick ◽  
Joaquim M.S. Cabral
Keyword(s):  
Stem Cell ◽  
Drug Discovery ◽  
High Throughput ◽  
Stem Cell Research

Industry Watch

2008 ◽  
Vol 12 (04) ◽  
pp. 22-30 ◽  
Keyword(s):  
Stem Cell ◽  
Drug Discovery ◽  
Stem Cell Research ◽  
Joint Venture ◽  
Documentation System ◽  
Regional Office ◽  
Drug Discovery And Development ◽  
Research Tools

Arana Achieves Milestone in Collaboration with CSL Limited. BI Biotech India and GlobalStem Inc Partner to Provide Stem Cell Research Tools in India. Zydus Cadila and Prolong Pharmaceuticals Collaborates in Drug Discovery and Development. Amgen and Takeda Announce Exclusive Collaboration in Japan. Bausch & Lomb and CrystalGenomics Announce R&D Collaboration. Emergent BioSolutions (EBS) and Ninebio Sdn Bhd Announce Joint Venture in Malaysia. Syngene Installs the First G: BOX HR Gel Documentation System in Jurong Island, Singapore. Swiss Biopharmaceutical Actelion Opens Regional Office in Singapore.

scholarly journals Concise Review: Increasing the Validity of Cerebrovascular Disease Models and Experimental Methods for Translational Stem Cell Research

Stem Cells ◽  
2017 ◽  
Vol 35 (5) ◽  
pp. 1141-1153 ◽  
Author(s):  
Johannes Boltze ◽  
Franziska Nitzsche ◽  
Jukka Jolkkonen ◽  
Gesa Weise ◽  
Claudia Pösel ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cerebrovascular Disease ◽  
Stem Cell Research ◽  
Experimental Methods ◽  
Disease Models ◽  
Concise Review

scholarly journals Pluripotent Stem Cell-Derived Hepatocytes Phenotypic Screening Reveals Small Molecules Targeting the CDK2/4-C/EBPα/DGAT2 Pathway Preventing ER-Stress Induced Lipid Accumulation

2020 ◽  
Vol 21 (24) ◽  
pp. 9557
Author(s):  
Maddalena Parafati ◽  
Sang Hyo Bae ◽  
R. Jason Kirby ◽  
Martina Fitzek ◽  
Preeti Iyer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Liver Disease ◽  
Drug Discovery ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Pluripotent Stem Cell ◽  
Cyclin D3 ◽  
High Content Screening ◽  
Alcoholic Fatty Liver ◽  
Cell Based Therapy

Non-alcoholic fatty liver disease (NAFLD) has a large impact on global health. At the onset of disease, NAFLD is characterized by hepatic steatosis defined by the accumulation of triglycerides stored as lipid droplets. Developing therapeutics against NAFLD and progression to non-alcoholic steatohepatitis (NASH) remains a high priority in the medical and scientific community. Drug discovery programs to identify potential therapeutic compounds have supported high throughput/high-content screening of in vitro human-relevant models of NAFLD to accelerate development of efficacious anti-steatotic medicines. Human induced pluripotent stem cell (hiPSC) technology is a powerful platform for disease modeling and therapeutic assessment for cell-based therapy and personalized medicine. In this study, we applied AstraZeneca’s chemogenomic library, hiPSC technology and multiplexed high content screening to identify compounds that significantly reduced intracellular neutral lipid content. Among 13,000 compounds screened, we identified hits that protect against hiPSC-derived hepatic endoplasmic reticulum stress-induced steatosis by a mechanism of action including inhibition of the cyclin D3-cyclin-dependent kinase 2-4 (CDK2-4)/CCAAT-enhancer-binding proteins (C/EBPα)/diacylglycerol acyltransferase 2 (DGAT2) pathway, followed by alteration of the expression of downstream genes related to NAFLD. These findings demonstrate that our phenotypic platform provides a reliable approach in drug discovery, to identify novel drugs for treatment of fatty liver disease as well as to elucidate their underlying mechanisms.

Sign in / Sign up

Export Citation Format

Share Document